Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.28 USD

2.28
7,179,830

+0.17 (8.06%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.26 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54.55% and 46.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 23.36% and 73.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of -2.27% and 46.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 31.25% and 154.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

NovoCure (NVCR) delivered earnings and revenue surprises of -79.41% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

by Zacks Equity Research

ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.

Zacks Equity Research

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

by Zacks Equity Research

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.